Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RCKT 
Rocket Pharmaceuticals Inc (RCKT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: RCKT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
18 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $41.6
Year Target Price $41.6
| 12 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.28% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 272.58M USD | Price to earnings Ratio - | 1Y Target Price 9.03 |
Price to earnings Ratio - | 1Y Target Price 9.03 | ||
Volume (30-day avg) - | Beta 0.68 | 52 Weeks Range 2.19 - 26.98 | Updated Date 06/29/2025 |
52 Weeks Range 2.19 - 26.98 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.8% | Return on Equity (TTM) -60.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -21851134 | Price to Sales(TTM) - |
Enterprise Value -21851134 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.77 | Shares Outstanding 107738000 | Shares Floating 81461718 |
Shares Outstanding 107738000 | Shares Floating 81461718 | ||
Percent Insiders 2.73 | Percent Institutions 93.45 |
Analyst Ratings
Rating 4.61 | Target Price 41.6 | Buy 5 | Strong Buy 12 |
Buy 5 | Strong Buy 12 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rocket Pharmaceuticals Inc
Company Overview
History and Background
Rocket Pharmaceuticals, Inc. was founded in 2015. It is a clinical-stage biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
Core Business Areas
- Hematologic Malignancies: Development of lentiviral vector (LVV)-based gene therapies for hematologic malignancies.
- Inherited Metabolic Disorders: Development of adeno-associated virus (AAV)-based gene therapies for inherited metabolic disorders.
Leadership and Structure
Gaurav Shah serves as the Chief Executive Officer. The company has a board of directors and various departments including research and development, clinical operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- RP-A501 (Danon Disease): An AAV9-based gene therapy for Danon Disease. Currently in clinical trials. Competitors include other companies developing gene therapies for cardiac diseases, though none are specifically targeting Danon Disease with the same approach at the same stage of clinical development. Market share data not yet available due to clinical stage.
- RP-L201 (LAD-I): A lentiviral vector (LVV)-based gene therapy for Leukocyte Adhesion Deficiency-I (LAD-I). Currently in clinical trials. Competitors include bone marrow transplantation and supportive care. Market share data not yet available due to clinical stage.
- RP-L102 (Fanconi Anemia Group A (FA-A)): A lentiviral vector (LVV)-based gene therapy for Fanconi Anemia Group A (FA-A). Currently in clinical trials. Competitors include bone marrow transplantation and supportive care. Market share data not yet available due to clinical stage.
- RP-L301 (Pyruvate Kinase Deficiency (PKD)): A lentiviral vector (LVV)-based gene therapy for Pyruvate Kinase Deficiency (PKD). Currently in clinical trials. Competitors include other companies developing therapies for PKD. Market share data not yet available due to clinical stage.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advances in vector technology and increasing regulatory approvals. It's characterized by high research and development costs, long development timelines, and significant regulatory hurdles.
Positioning
Rocket Pharmaceuticals focuses on rare pediatric diseases. Its competitive advantage lies in its proprietary gene therapy platforms and clinical trial progress.
Total Addressable Market (TAM)
The total addressable market (TAM) for gene therapies targeting rare diseases is estimated to be in the billions of dollars annually. Rocket Pharma's positioning hinges on successfully navigating clinical trials and securing regulatory approvals to capture a significant portion of this TAM.
Upturn SWOT Analysis
Strengths
- Strong pipeline of gene therapy candidates
- Proprietary gene therapy platforms (AAV and LVV)
- Experienced management team
- Focus on rare and unmet medical needs
- Advanced clinical trial stages for key assets
Weaknesses
- High cash burn rate due to R&D expenses
- Dependence on successful clinical trial outcomes
- Reliance on regulatory approvals
- Small market sizes for target diseases may limit revenue potential
- Manufacturing complexities and scalability challenges
Opportunities
- Potential for accelerated regulatory pathways (e.g., orphan drug designation)
- Expansion of pipeline through new targets and technologies
- Strategic partnerships with larger pharmaceutical companies
- Increased awareness and acceptance of gene therapy
- Positive clinical data driving increased investor confidence
Threats
- Clinical trial failures
- Adverse events or safety concerns
- Regulatory delays or rejection
- Competition from other gene therapy companies
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- BLUE
Competitive Landscape
Rocket faces competition from other gene therapy companies, larger pharmaceutical companies, and traditional treatment options. Its focus on rare diseases may limit its market size but also provides opportunities for orphan drug designation and faster regulatory pathways.
Growth Trajectory and Initiatives
Historical Growth: Growth is measured by the advancement of its gene therapy candidates through clinical trials.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of its gene therapies. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for RP-A501, RP-L201, RP-L102, RP-L301 and expanding its manufacturing capabilities.
Summary
Rocket Pharmaceuticals is a clinical-stage biotech company with a promising pipeline of gene therapies for rare diseases. Successful clinical trials and regulatory approvals are crucial for its growth. The company faces risks associated with clinical trial failures, competition, and high R&D expenses. Positive clinical data will bolster investor confidence and drive stock price appreciation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Rocket Pharmaceuticals' Investor Relations website
- SEC filings (10-K, 10-Q)
- ClinicalTrials.gov
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data and analysis are based on publicly available information and are subject to change without notice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rocket Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cranbury, NJ, United States | ||
IPO Launch date 2015-02-18 | CEO & Director Dr. Gaurav D. Shah M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 299 | Website https://www.rocketpharma.com |
Full time employees 299 | Website https://www.rocketpharma.com | ||
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; REGENXBIO, Inc.; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.